Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the compensation committee of the company's board of directors granted four new employees options to purchase a total of 11,200 shares of the company's common stock at an exercise price per share of $19.85, which was the closing price on may 8, 2023, and rest.
RCUS Ratings Summary
RCUS Quant Ranking